Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Lixte Biotechnology Holdings (LIXT) EBIT (2016)

Lixte Biotechnology Holdings' EBIT history spans 7 years, with the latest figure at -$516268.0 for Q4 2016.

  • For Q4 2016, EBIT changed N/A year-over-year to -$516268.0; the TTM value through Dec 2016 reached -$2.1 million, changed N/A, while the annual FY2025 figure was -$5.1 million, 42.96% down from the prior year.
  • EBIT reached -$516268.0 in Q4 2016 per LIXT's latest filing, up from -$647077.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$313052.0 in Q3 2013 to a low of -$11.2 million in Q4 2013.
  • Average EBIT over 5 years is -$1.7 million, with a median of -$536148.5 recorded in 2014.
  • Peak YoY movement for EBIT: skyrocketed 62.65% in 2013, then crashed 114.34% in 2014.
  • A 5-year view of EBIT shows it stood at -$9.9 million in 2012, then fell by 13.95% to -$11.2 million in 2013, then soared by 95.53% to -$501420.0 in 2014, then plummeted by 55.5% to -$779712.0 in 2015, then skyrocketed by 33.79% to -$516268.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's EBIT are -$516268.0 (Q4 2016), -$647077.0 (Q3 2016), and -$555017.0 (Q2 2016).